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The aim of cancer vaccines is induction of tumor-specific cytotoxic T lymphocytes (CTLs) that can reduce the tumor mass.
Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune
responses. Thus, DCs-based vaccination represents a potentially powerful strategy for induction of antigen-specific CTLs. Fusions
of DCs and whole tumor cells represent an alternative approach to deliver, process, and subsequently present a broad spectrum of
antigens, including those known and unidentified, in the context of costimulatory molecules. Once DCs/tumor fusions have been
infused back into patient, they migrate to secondary lymphoid organs, where the generation of antigen-specific polyclonal CTL
responses occurs. We will discuss perspectives for future development of DCs/tumor fusions for CTL induction.
1. Introduction
A major area of investigation in cancer vaccines involves the
design of dendritic cells- (DCs-) based cancer vaccines. DCs
can be distinguished from B lymphocytes and macrophages
by their abundant expression of costimulatory molecules
and efficient ability to prime both CD4+ helper and CD8+
cytotoxic activities [1]. Exogenous antigens from tumor cells
can be taken up by DCs and translocated to the cytoplasm,
processed, and presented through endogenous pathway. Both
immature and mature DCs are capable of processing and
presenting MHC-peptide complexes to T cells. Mature DCs
are significantly better at CTL induction due to higher
expression of MHC and costimulatory molecules, while
presentation of antigens by immature DCs, in the absence
of proper costimulation, may lead to tolerance induction
[2, 3]. After antigens uptake and inflammatory stimulation,
immature DCs in peripheral tissues undergo a maturation
process characterized by the upregulation of costimulatory
molecules. During this process, mature DCs migrate to the
regional lymph nodes, where they present antigens to CD4+
and CD8+ T cells through MHC class I and II pathways
[1–3].
Loading MHC class I and II molecules on the cell surface
of DCs with peptides derived from defined tumor-associated
antigens (TAAs) is the most commonly applicable strategy
for DCs-based cancer vaccines. This strategy has some
limitations: (1) a limited number of known tumor peptides
available in many HLA contexts whose immunogenicity is
uncertain and (2) the relatively rapid turnover of exogenous
peptide-MHC complexes that results in comparatively low
antigen-presentation by DCs. Although DCs pulsed with
antigen-specific peptides have been used in clinical trials
for cancer patients, clinical responses have been found
in a small number of patients [4, 5]. Another strategies
have been developed to load DCs with TAAs, including
tumor RNA, tumor lysates, and dying tumor cells to induce
antigen-specific CTL responses [6–10]. DCs pulsed with
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apoptotic tumor cell fragments or tumor lysates rely on
antigen being cross-presented, all of which are usually not
efficient [11]. An alternative strategy for inducing efficient
CTL responses is the use of fusion cells generated by
fusing DCs and tumor cells by polyethylene glycol (PEG)
known as a chemical membrane destabilizing agent [12]. In
this approach, multiple TAAs, including both known and
unidentified, are delivered to DCs, endogenously processed
and presented through MHC class I and II pathways in the
context of the potent immune-stimulatory machinery of the
DCs [13–15].
2. DCs/Tumor Fusions Approach
The chemical agent PEG [12], electroporation [16], and
many viruses [17] have been used for the cell fusion strategy.
We have used PEG to generate fusions of DCs and tumor
cells. In our approach, DCs are usually mixed with tumor
cells at a ratio of 10 : 1 in serum-free prewarmed RPMI
1640 medium. After centrifuge, mixed cell pellets are gently
resuspended in prewarmed 50% PEG solution (molecular
weight = 1,450)/DMSO solution, Sigma-Aldrich, St. Louis,
MO; 1 mL per 5× 106 cells) for 3 to 5 minutes at room
temperature. Subsequently, the PEG solutions are diluted
by slow addition and mixed with 1, 2, 4, 8, and 16 mL
of serum-free prewarmed RPMI medium until 50 mL. The
cell pellets are resuspended in prewarmed RPMI 1640
supplemented with 10% autologous heat-inactivated serum,
GM-CSF (1000 units/mL), and IL-4 (500 units/mL) and
cultured in a 5% CO2 atmosphere at 37◦C for 3 days. The
DCs/tumor fusions cannot proliferate but alive until 5 to 7
days after fusion (our unpublished data). Therefore, we have
usually cultured fusion cells for 3 days after PEG treatment.
After 3 days of culture, DCs/tumor fusion preparations are
integrated into a single entity and are loosely adherent to the
culture dish. Unfused tumor cells grow firmly attaching to
the plates, whereas DCs/tumor fusions are loosely adherent
in the culture wells. DCs/tumor fusions can be selected
and purified by gentle pipetting, and firmly attached tumor
cells are discarded. As this fusion procedure delivers not
only the TAAs-epitopes but also the genes encoding the
TAAs, DCs/tumors can continue to produce TAAs for
several days after fusion [18]. Because fusion efficiency
is closely correlated with antitumor immune responses in
mice study, DCs/tumor fusions have been harvested on
3 days after fusion process to induce CTL responses in
vitro.
There are some methods for enrichment of DCs/tumor
fusion cells by FACS cell sorting [19] and the transfection
of DCs with Tyr-green fluorescent protein reporter virus
[20]. On the other hand, short-term culture of fusion cell
preparations can also promote DCs/tumor fusion efficiency
and reduce cell aggregates [18]. Therefore, it is not nec-
essary to enrich DCs/tumor fusion cell preparations using
special methods. In clinical trials and animal studies, fusion
cell preparations, including fused cells, unfused DCs, and
unfused tumor cells, have been irradiated before vaccination
[12, 18, 21, 22].
3. Characterization of DCs/Tumor Fusions
Fusions of DCs and whole tumor cells have the essen-
tial elements for processing and presenting TAAs to host
immune cells and inducing effective antitumor immune
responses (Figure 1). It has been known that there are
two different pathways for antigen presentation by DCs.
Endogenously synthesized proteins, such as those in viral
infections, and certain exogenous antigens are processed
and presented through the MHC class I-restricted pathway
to CD8+ T cells [1–3]. In contrast, exogenous antigens
are processed through endogenous pathway, a phenomenon
called cross-antigen presentation and displayed in asso-
ciation with MHC class II molecules and recognized by
CD4+ T cells [1–3]. Importantly, the fusion process facil-
itates the introduction of tumor antigen to endogenous
antigen processing pathway [23]. It has been reported
that DCs/tumor fusions have the ability to process and
present intracellular proteins derived from tumor cells
[24]. Advantage of DCs/tumor fusions strategy over DCs
pulsing with tumor lysates is that endogenously synthesized
antigens have better access to MHC class I pathway [25].
Indeed, DCs/tumor fusions vaccine is superior to those
involving other methods of DCs loading with antigenic
proteins, peptides, tumor cell lysates, or irradiated tumor
cells [26].
The membranes of DCs/tumor fusions are integrated
into a single cell, whereas the nuclei remain separate in
the primary hybrid cells [27]. Therefore, the important
advantage in DCs/tumor fusions strategy is that modifica-
tions of DCs and tumor cells are independently possible
while their characters persist after the fusion. This is an
important difference between the DCs/tumor fusions and
DCs pulsed with whole tumor cells. The fusions deliver not
only the TAAs but also the mRNA encoding the TAAs. It has
been reported that there are differences in the translation
efficiency of mRNA to protein between immature DCs
and mature DCs [15]. Stimulation of DCs by Toll-like
receptor (TLR) signaling results in increased expression
of peptide/MHC class I and II complexes, costimulatory
molecules (CD80 and CD86), and IL-12 [28]. Recent
studies have shown that cross-presentation is based on the
transfer of proteasome substrates that are transcriptionally
upregulated by heat-treatment of tumor cells [29, 30].
Therefore, we have generated fusions of TLR-stimulated
DCs and heat-treated tumor cells to induce efficient CTL
induction (Figure 2). This modified DCs/tumor fusions have
been more potent than conventional fusions generated with
immature DCs and unheated tumor cells, as demonstrated
by (1) upregulation of heat-shock proteins (HSPs), MHC
class I and II, TAAs, CD80, CD86, CD83, and IL-12; (2)
activation of CD4+ and CD8+ T cells able to produce IFN-
γ at higher levels; and (3) potent induction of antigen-
specific CTL responses [30]. Synergism between TLR-
stimulated DCs and heat-treated tumor cells may enhance
the immunogenicity of DCs/tumor fusions and may provide
promising means of inducing therapeutic CD4+ and CD8+
T cells.
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Figure 1: Antigen-processing and -presentation by DCs/tumor fusions. DCs/tumor fusions express MHC class I and II, costimulatory
molecules (CD80 and CD86), and multiple tumor-associated antigens. The DCs/tumor fusions are able to process multiple tumor-derived
peptides and MHC class I peptides derived from tumor and DCs. They form MHC class I-peptide complexes, in the endoplasmic reticulum,
which are transported to the cell surface of fusions and presented to CD8+ T cells. The DCs/tumor fusions can also synthesize MHC class II
peptides derived from DCs in the endoplasmic reticulum, which are transported to the cytoplasm, where MHC class II-peptide complexes
are assembled with multiple tumor-derived peptides. These complexes are presented to CD4+ T cells, which are essential for induction of
antigen-specific polyclonal CTLs.
4. Induction of CTL Responses by DCs/Tumor
Fusions in Animal Models
MUC1, a carcinoma-associated antigen, is a high-molecular-
weight glycoprotein overexpressed in human breast, pancre-
atic, colon, and other carcinomas [31, 32]. Therefore, we
have used MUC1-transgenic (MUC1.Tg) mice as a preclin-
ical model in initial animal studies. Although the MUC1.Tg
mice expressing human MUC1 was unresponsive to MUC1
antigen, MUC1-specific CTL responses could be efficiently
generated by fusions of DCs and MUC1-positive carcinoma
cells [33]. Moreover, MUC1-specific CTLs rejected the
established MUC1-expressing tumor metastases [33–35]. On
the other hand, there was little if any anti-MUC1 CTL
responses could be induced with DCs transfected with
MUC1 RNA in MUC1.Tg mice [10]. Unresponsiveness to
the MUC1 antigen could be reversible by vaccination with
DCs/tumor fusions expressing MUC1. Therefore, the fusions
vaccine may represent an effective strategy for the treatment
of human tumors. The DCs/tumor fusions vaccine not only
provided protection against challenge with tumor cell, but
also regressed the established tumors, including melanoma
[11, 19, 24, 36–40], colorectal [12, 20, 34, 41–48], breast [49–
53], esophageal [54], pancreatic [55], hepatocellular [56–
60], lung [61, 62], laryngeal [63], renal cell carcinoma [64],
sarcoma [65–67], myeloma [68–73], mastocytoma [74], and
neuroblastoma [75].
The transplantable tumor models have been contributed
as the primary screening tools for cancer vaccine devel-
opment. However, tumor in these models grows very
quickly without the multiple stages of cancer development
found in human cancers. Mice with spontaneous tumor
development provide a powerful tool to study the efficacy
of CTL induction, since they mimic tumor development
in humans. We have used a transgenic murine model
(MMT mice) expressing polyomavirus middle T oncogene
and MUC1 antigen [32, 76]. The MMT mice developed
mammary carcinoma between the ages of 65–108 days
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Figure 2: Modified DCs/tumor fusions. (a) Conventional fusions generated with immature DCs and unheated tumor cells express MHC
class I and II, costimulatory molecules (CD80 and CD86), Toll-like receptor (TLR), and multiple tumor-associated antigens (TAAs). (b)
Fusions generated by fusing TLR-stimulated DCs and heat-stressed tumor cells have characteristic phenotype with upregulation of multiple
HSPs, MHC class I and II, costimulatory molecules (CD80 and CD86), maturation marker CD83, multiple TAAs, and IL-12. As compared
with conventional fusions (a), synergism between TLR-stimulated DCs and heat-stressed tumor cells enhances the immunogenicity of
DCs/tumor fusions.
with 100% penetrance. Prophylactic vaccination of MMT
mice with DCs/tumor fusions induced polyclonal CTLs
against spontaneous mammary carcinoma cells and rendered
57%–61% of the mice free of the disease at the end of
experiment (180 days) [50, 51]. In other mice models
that develop spontaneous hepatocellular carcinoma [58] or
gastrointestinal cancer [43], DCs/tumor fusions were also
capable of inducing CTL responses.
5. How to Induce CTL Responses by
DCs/Tumor Fusions
The DCs/tumor fusions possess the properties of both parent
cells. Fusions of DCs and tumor cells result in the formation
of a heterokaryon that combines DC-derived MHC class I
and II, costimulatory molecules, efficient antigen-processing
and -presentation machinery, and abundant tumor-derived
MHC class I and TAAs (Figure 1) [12]. The DCs/tumor
fusions approach facilitates the entry of TAAs that are
synthesized de novo in the fusions. As a result, whole TAAs
can be processed and presented through both MHC class I
and II pathways on the DC compartment in the context of
costimulatory molecules [12]. The advantage of DCs/tumor
fusions over DCs loading with tumor lysates or peptide is
that endogeneously synthesized TAAs have better access to
MHC class I and II pathways [25]. Effective TAAs processing
and presentation in DCs/tumor fusions are crucial for potent
CTL induction.
MHC class I and II molecules are important for antigen
processing and presentation and subsequent activation of
CD8+ and CD4+ T cells, respectively. To investigate the role
of MHC class I- and II-restricted antigen presentation and
the activation of CD4+ and CD8+ T cells by DCs/tumor
fusion cells, we have created four types of DCs/tumor fusions
with intact or deficient expressions of MHC class I and/or
II molecules by using several kinds of DCs from MHC
class I and/or II knockout mice and tumors: (1) wild type
fusions (WT-FCs), (2) MHC class I knockout fusions (IKO-
FCs), (3) MHC class II knockout fusions (IIKO-FCs), and
(4) MHC class I and II knockout fusions (I/IIKO-FCs)
[77]. We observed differential impairment of antitumor
immunity induced by fusions generated with DCs from
MHC class I and/or II knockout mice. Immunization of
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mice with IKO-FCs resulted in slightly decreased capacity
for CTL induction, tumor prevention, and tumor treatment,
compared with immunization with WT-FCs. In contrast,
immunization with IIKO-FCs abolished IFN-γ production
of CD4+ and CD8+ T cells and the induction of CTLs and
exhibited severely impaired antitumor immunity. Therefore,
MHC class II antigen presentation targeting activation of
CD4+ T cells may be indispensable in antitumor immunity.
The presentation of TAAs on MHC class II is essential
for the activation of CD4+ T cells and the induction of
efficient CD8+ CTL responses. It has been demonstrated that
predominant effector cells are CD8+ CTLs, as most tumors
express only MHC class I molecules. However, there are
increasing evidences that CD4+ T cells play a more direct role
beyond delivery of assistance in the generation of efficient
antitumor immunity [78]. Unlike CD8+ T cells, CD4+ T
cells may contribute to antitumor immunity through diverse
mechanisms. It has been well documented that CD4+ T cells
provide help to CD8+ T cells by activating APCs through
CD40-CD40L interaction [79] and/or IL-2 production [80].
In addition to providing help in the priming phase, CD4+ T
cells are also essential in the effector phase [81], in which they
are required for the maintenance of CD8+ CTLs in vivo and
the infiltration of CTLs at the tumor site [82]. Importantly, it
has been also reported that adoptive cell transfer of antigen-
specific CD4+ T cells can control tumor growth [83].
6. Stimulation of CD4+ and CD8+ T Cells by
DCs/Tumor Fusions
Efficient CTL induction requires the stimulation of both
CD4+ and CD8+ T cells [84]. We have previously reported
that DCs/tumor fusions migrated to the regional lymph
nodes, where they were closely associated with CD4+ and
CD8+ T cells. Moreover, DCs/tumor fusions localized to
the T cell area in the regional lymph nodes and formed
clusters with CD4+ and CD8+ T cells [34]. Simultaneous
recognition of cognate peptides presented by MHC class I
and II molecules on DCs/tumor fusions is essential in the
induction of efficient CTLs [84, 85]. DCs/tumor fusions,
unlike DCs, do not have to take up exogenous TAAs.
Moreover, DCs or Langerhans cells in the patient body
can intake the degraded DCs/tumor fusions that have been
vaccinated. Therefore, both direct antigen-presentation by
DCs/tumor fusions and cross-presentation by DCs in the
patients with cancer can participate in CD4+ and CD8+
T cell-activation [14, 45, 84]. It has been well known that
mature DCs are significantly better at CTL induction due
to higher expression of MHC and costimulatory molecules,
while presentation of TAAs by immature DCs, in the absence
of proper costimulation, may lead to tolerance induction
[86]. Recent studies indicate that TLRs directly regulate
both cancer immunity and tolerance through innate immune
responses mediated by regulatory T cells (Tregs), DCs, and
other immune cells [87]. Coadministration of TLR ligands
with DCs/tumor fusion-based vaccine regulates the function
of Tregs and DCs through some mechanisms: (1) stimulation
of fusions by TLR signaling results in the increased expres-
sion of peptide/MHC class I and II complexes, costimulatory
molecules (CD80 and CD86), and cytokines (IL-12) [18],
and (2) TLR signaling activation on fusions can render
naive T cells refractory to suppression mediated by Tregs
[88]. TLR ligands also activate DCs at the tumor site
and enhance antigens cross-presentation, migration into
regional lymph node, and induction of antigen-specific
CTL responses [87, 89]. Importantly, TLR ligands prevent
the death of activation-induced CTLs by increasing the
expression of antiapoptotic mediators (Bcl-xL and c-FLIP),
allowing these cells to survive and migrate into the tumor
site [90]. Moreover, the apoptosis of DCs can potentially
regulate DCs homeostasis and immune responses. It has been
reported that Bim, a BH3 protein of the Bcl-2 family, is
important for regulating spontaneous cell death of DCs [91].
Therefore, enhanced DCs/tumor fusions survival may play a
role in efficient CTL inductions.
Another effective adjuvants for enhancing the induction
of CD4+ and CD8+ T cells are HSPs, to which the ability
of heat-treated tumor cells to enhance immunogenicity
has been attributed [92]. Recently it has been shown
that cross-priming is based on the transfer of proteasome
substrates that are transcriptionally upregulated by heat-
treatment of tumor cells [29]. This is potentially impor-
tant in the rational design for cancer vaccines that elicit
CD8+ CTL responses. This concept offers additional effects
by which heat treatment of tumor cells might enhance
antigen-processing and -presentation in MHC class I and II
molecules on the surfaces of DCs/tumor fusions. Moreover,
extracellular HSPs act as a chaperon and interact with DCs
in a receptor-mediated manner, leading to DCs matura-
tion as well as proinflammatory responses, all of which
are essential for induction of effective CD4+ and CD8+
CTL responses. Recently, we have shown that heat shock
protein 70-peptide complexes (HSP70.PCs) derived from the
DCs/tumor fusions possess superior properties compared
with HSP70.PCs from tumor cells in animal and human
models [93, 94]. Namely, HSP70.PCs derived from human
DCs/tumor fusions induced T cells that expressed higher
levels of IFN-γ and exhibited increased levels of killing of
tumor cells, compared with those induced by HSP70.PCs
derived from tumor cells. Enhanced immunogenicity of
HSP70.PCs from DCs/tumor fusions was associated with
improved composition of the vaccine, including increased
content of TAAs and their processed intermediates, and the
detection of other heat HSPs such as HSP90 and HSP110
[94].
7. Induction of Antigen-Specific
Polyclonal CTL Responses Restricted by
MHC Class I and II Molecules
Cancer vaccine approaches that rely on induction of
immunity against particular antigens are potentially subject
to tumor cell resistance mediated by the downregulation
of the single antigen. Therefore, induction of polyclonal
antigen-specific CTL responses may have the potential to
maximize the protection against various subsets of tumor
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cells downregulated by certain tumor antigens, which may
appear during the course of tumor progression. Fusions of
DCs and autologous tumor cells are effective for induction of
antigen-specific polyclonal CTL responses. How the fusions
assemble and present the MHC class I-restricted multiple
peptide complexes is unclear. One possibility is that multiple
peptides are complexed with MHC class I molecules in tumor
cells and the complexes are simply transferred to the fusion
cells. Alternatively, the tumor cells may provide multiple
tumor antigens and the fusion process simply facilitates the
delivery of tumor antigens to the efficient antigen-processing
and -presenting machinery in DCs. Then the tumor antigens
are presented in the context of MHC class I and II molecules
derived from DCs. We have demonstrated that fusions
generated with allogeneic tumor cells and autologous DCs
induced polyclonal antigen-specific CD4+ and CD8+ T cells
restricted by autologous MHC class I and II molecules [95,
96]. These results suggest that the TAAs from allogeneic
tumor cells are processed along the endogenous pathway,
through the antigen-processing machinery of autologous
DCs. Indeed, stimulation of T cells with fusions resulted
in MHC class I and II restricted CD4+ and CD8+ T
cell proliferation, high levels of IFN-γ production in both
CD4+ and CD8+ T cells, and the simultaneous induction
of polyclonal antigen-specific CTL responses restricted by
multiple HLA molecules [84, 95–101].
8. Generation of Tregs by DCs/Tumor Fusions
Immature DCs are one of the mediators of tolerance
induction. In peripheral lymphoid organs immature DCs
are incapable of eliciting CTL responses. In contrast, if a
stimulus for DCs activation is sufficiently coadministered
with antigens, mature DCs express high levels of costim-
ulatory molecules, resulting in priming of antigen-specific
CTL induction rather than Tregs [86]. There are increasing
evidences that tumor-derived soluble factors such as TGF-β
and IL-10 promote the induction of tolerance through the
generation of CD4+ CD25high Foxp3+ Tregs, which may
be linked to compromised immune responses in patients
with cancer [102]. In animal models, tumor-derived TGF-β
reduces the efficacy of DCs/tumor fusion vaccine via in vivo
mechanisms [42]. Moreover, the blockade of tumor-derived
TGF-β reduces Treg generation by the DCs/tumor fusions
and enhances antitumor immunity [52]. Indeed, the potent
immunosuppressive effects by Tregs can explain the failure
of many immunotherapeutic approaches to patients with
cancer [103]. In our study, fusions of immature DCs gen-
erated in the presence of tumor-derived culture supernatants
promoted the generation of CD4+ CD25high Foxp3+ Tregs
and inhibited CTL induction [88]. Recently, it has also been
demonstrated that fusions in human are effective APCs to
induce CTL responses but to stimulate inhibitory T cells
that limit vaccine efficacy. However, exposure of DCs to
TLR agonists, stimulatory cytokines, and anti-CD3/CD28
enhances vaccine efficacy by limiting the Treg responses
and promoting expansion of CTLs in vitro [104]. Depletion
of Tregs before vaccination may lead to enhanced CTL
responses in cancer patients [103]. If the immune-suppressed
environment in tumor is sufficiently improved, selective
manipulation for the innate immune responses induced by
TLR agonists may have more potential to promote DCs
maturation and CTL over Treg generation [97]. As many
tumors express or induce immunosuppressive cytokines such
as IL-10 and TGF-β in tumor environment, patients early
in the course of the disease are expected to respond best to
clinical responses by fusion cell vaccination. A combination
of control of Tregs and concomitant induction of CTLs may
be a more effective immunotherapy to reduce recurrence and
prolong survival after surgery.
9. Clinical Trials
Based on these unique features of DCs/tumor fusions,
initial Phase I/II clinical trials have been conducted in a
variety of tumors (Table 1). Fusion cell vaccination has been
reported in patients with melanoma [98, 99]. In the report,
autologous melanoma cells were fused to allogeneic DCs by
electrofusion and assessed them as a vaccine in 17 patients
with disseminated melanoma refractory to standard therapy.
One patient had a partial response with decrease in size
of all evaluable tumor manifestations. In one patient, some
of the metastases were regressed despite overall progressive
disease, and one patient achieved disease stabilization for 6
months. There were no serious side effects associated with
the administration of the vaccine. In our initial clinical
trial, 8 patients with malignant glioma were vaccinated with
fusions of autologous DCs and autologous tumor cells. In all
6 cases analyzed, the concentration of IFN-γ in the T cell
culture supernatant increased after vaccination. However,
clinical responses were not observed [101]. Therefore, we
conducted a phase I/II clinical study for the safety profile
of vaccination with DCs/tumor fusions combined with
recombinant human (rh) IL-12 in patients with malignant
brain tumor, melanoma, breast, gastric, colorectal, and
ovarian cancer [100, 105]. Eleven out of 15 patients with
malignant brain tumor achieved a stable response and 24
patients had a progressive disease after 8 weeks of the initial
treatment. The vaccine was well tolerated and no serious
adverse effects were observed. In four patients, magnetic
resonance imaging showed a greater than 50% reduction in
tumor size. One patient had a mixed response. Therefore,
coadministration of the fusions and rh IL-12 can induce
more effective antitumor effects than fusions alone in some
patients with malignant glioma. In this clinical trial, we
vaccinated patients with extremely small amounts of fusion
cells and rh IL-12 but resulted in immunological and clinical
responses in a subset of patients with malignant brain
tumor. The relatively favorable response to malignant brain
tumors is of particular interesting since the central nervous
system is generally considered to be an immunologically
privileged site as a result of the lack of lymphatic drainage
and the nature of the blood-brain barrier. However, these
studies demonstrated that appropriately activated T cells
could cross the blood-brain barrier to access the tumor
burden and initiated tumor regression. On the other hand,
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Table 1: Assessment of DCs/tumor fusions based vaccine.
Patients
DCs/tumor fusions
Coadministration Clinical responses Ref.
Dendritic cells Tumor cells
Melanoma (n = 16) Allogeneic Autologous 1 (CR) [98]
1 (PR)
5 (SD)
9 (PD)
Glioma (n = 8) Autologous Autologous 2 (PR) [101]
1 (SD)
5 (PD)
Melanoma (n = 17) Autologous Autologous 1 (PR) [99]
1 (SD)
15 (PD)
Melanoma (n = 11) Allogeneic Autologous rh IL-2 1 (SD) [100]
10 (PD)
Glioma (n = 12) Autologous Autologous rh IL-12 3 (PR) [100]
2 (MR)
4 (SD)
3 (PD)
Breast cancer (n = 2) Autologous Autologous rh IL-12 1 (SD) [100]
1 (PD)
Gastric/Colorectal cancer (n = 3) Autologous Autologous rh IL-12 1 (SD) [100]
2 (PD)
Ovarian cancer (n = 3) Autologous Autologous rh IL-12 2 (SD) [100]
1 (PD)
Melanoma (n = 4) Autologous Autologous rh IL-12 4 (PD) [100]
Breast cancer (n = 10) Autologous Autologous 2 (PR) [21]
1 (SD)
7 (PD)
Renal cell carcinoma (n = 20) Allogeneic Autologous 2 (PR) [22]
8 (SD)
10 (PD)
Hepatocellular carcinoma (n = 1) Autologous Autologous 1 (PD) [88]
CR: complete response; PR: partial response; MR: mixed response; SD: stable disease; PD: progressive disease.
patients with metastatic breast or renal cancer were also
treated with fusions of autologous DCs and autologous
tumor cells [21]. In this trial, 23 patients were vaccinated
by the fusions and no significant treatment-related toxicity
was observed. In a subset of patients, vaccination resulted
in immunological responses. Interestingly, 2 patients with
breast cancer exhibited disease regressions, including a near
complete response of a large chest wall mass. Five patients
with renal carcinoma and one patient with breast cancer
had disease stabilization. Recently, this group evaluated the
effect of vaccination with fusions of allogeneic DCs and
autologous tumor cells in patients with stage IV renal
cell carcinoma [22]. Vaccination of the fusions resulted in
antitumor immune responses in 10 (48%) of 21 evaluable
patients. Two out of 21 patients demonstrated a partial
clinical response and 8 patients had stabilization of their
disease. In clinical trials, only limited therapeutic results were
obtained; however, DCs/tumor fusions-based vaccine may
work more effectively in patients in the early stage of the
disease with low tumor burden after surgery, chemotherapy,
or irradiation.
In the clinical setting of the patients with cancer, a
major difficulty for the fusions vaccine is the preparation of
sufficient amounts of autologous tumor cells. The specimen
of tumor from primary lesion may not provide sufficient
numbers of viable tumor cells due to the length of culture
time and potential contamination of bacteria and fungus.
We have reported that fusions of autologous DCs and
allogeneic tumor cell lines induced CTL responses against
the autologous tumor cells [95, 96]. The basis for using
allogeneic tumor cell lines instead of autologous tumor
cells is that some antigens are shared by most of tumors.
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This strategy has numerous advantages. (a) Allogeneic tumor
cell lines are well characterized as TAA source. (b) Allogeneic
tumor cell lines, which share with TAAs, can grow well
in vitro; thus, there is no limiting factor for preparation
of tumor cells. (c) It is not necessary to determine HLA
typing of patients and allogeneic tumor cells as a partner of
fusion cells, because autologous DCs can process and present
multiple TAAs from allogeneic tumor cells in the context of
MHC class I and class II molecules. The clinical trials using
allogeneic fusions have not been reported yet.
10. Future Directions
Although fusion cell vaccination is effective to induce CTL
responses, we are searching for optimal strategy to benefit
patients significantly. DCs/tumor fusion cell vaccine alone
may be insufficient to have a significant contribution to
treat advanced cancer patients with compromised immune
system. To elicite polyclonal CTL induction in patients with
cancer, it may be necessary to combine with chemotherapy,
radiotherapy, hormonal therapy, or photodynamic ther-
apy to reduce Treg and enhance CTL responses. Indeed,
the combination therapy of fusion cell vaccination and
adoptive immunotherapy is a very effective against poorly
immunogenic carcinomas in murine studies [41, 53, 106].
Combination with these approaches has enormous potential
to improve the current outcomes from conventional cancer
therapy. The next decade will see the first clinical trials testing
whether combination of induction of augmented CTLs and
depletion of Tregs might be effective in treatment for cancer
patients.
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